FDA paus­es Mer­sana’s clin­i­cal tri­al af­ter pa­tient dies

3 years ago
FDA+

Cal­lid­i­tas plans to file for full ap­proval for rare kid­ney dis­ease drug fol­low­ing PhI­II da­ta

3 years ago
R&D
FDA+

Up­dat­ed: Carl Ic­ahn pro­pos­es three new Il­lu­mi­na board mem­bers in proxy fight

3 years ago
People
Startups

Up­dat­ed: Pfiz­er to buy Seagen for $43B, end­ing long-run­ning M&A saga for biotech

3 years ago
Deals
Pharma

Sanofi to pay $2.9B for Proven­tion Bio and its di­a­betes-de­lay­ing drug Tzield

3 years ago
Deals
Pharma

Up­dat­ed: Aca­dia wins first FDA ap­proval for Rett syn­drome drug

3 years ago
FDA+

Sil­i­con Val­ley Bank cus­tomers to have all funds ac­ces­si­ble, US says, eas­ing biotech and tech tur­moil

3 years ago
Financing
Startups

Sil­i­con Val­ley Bank shut­ters; Rare dis­ease tri­als can't find enough pa­tients; FDA ad­comm votes in fa­vor of Po­livy ...

3 years ago
Weekly

Re­pub­li­can sen­a­tors slam pro­posed ac­cel­er­at­ed ap­proval pay­ment re­forms

3 years ago
Pharma
FDA+

FDA will phase out 22 Covid-19 guid­ance doc­u­ments as emer­gency de­c­la­ra­tion ex­pires

3 years ago
Pharma
FDA+

FDA sched­ules ad­comms for En­ta­sis' an­timi­cro­bial treat­ment, In­ter­cep­t's NASH hope­ful

3 years ago
FDA+

GAO to FDA: Do more to en­cour­age drug man­u­fac­tur­ing in­no­va­tion

3 years ago
FDA+
Manufacturing

Am­gen delves in­to re­la­tion­ships and asth­ma with not­ed ther­a­pist and au­thor

3 years ago
Pharma
Marketing

Ei­sai projects $7B in sales by 2030 for new Alzheimer's drug

3 years ago
Pharma

Con­gress moves bill re­quir­ing de­clas­si­fi­ca­tion of Covid-19 ori­gins in­fo to Biden's desk

3 years ago
Coronavirus

Sil­i­con Val­ley Bank, which served bio and tech sec­tors, is shut down af­ter days of tur­moil

3 years ago
Pharma

Al­lo­ri­on rais­es $50M Se­ries B; AskBio gets a new CEO

3 years ago
News Briefing

Mod­er­na looks to the West Coast for lat­est ex­pan­sion

3 years ago
Pharma
Manufacturing

Pfiz­er's mi­graine nasal spray from Bio­haven notch­es ap­proval

3 years ago
Pharma
FDA+

Ver­tex heads to the clin­ic with a next-gen stem cell can­di­date for type 1 di­a­betes

3 years ago
R&D
FDA+

Up­dat­ed: Wor­ries over Sil­i­con Val­ley Bank rip­ple through tech and biotech star­tups, VCs

3 years ago
Financing
Deals

Ver­san­t's new im­munol­o­gy biotech San­ta Ana Bio snags Se­ries A with GV, TPG part­ners on board

3 years ago
Financing
Startups

Bio­gen looks to its bench to re­place chair­man Pa­padopou­los; Lil­ly, Ab­b­Vie gene ther­a­py part­ner makes CSO hire

3 years ago
Peer Review

Ole­ma On­col­o­gy to cut 25% of staff, says it will fo­cus on late-stage pipeline

3 years ago
People
R&D
First page Previous page 363364365366367368369 Next page Last page
A service from the Financial Times